In This Article:
In the wake of a significant U.S. election outcome, global markets have experienced notable shifts, with U.S. stocks rallying to record highs amid expectations of growth-friendly policies and tax reforms. As investors navigate these dynamic conditions, dividend stocks emerge as a compelling option for those seeking stability and income potential in their portfolios amidst market volatility and evolving economic landscapes.
Top 10 Dividend Stocks
Name | Dividend Yield | Dividend Rating |
Peoples Bancorp (NasdaqGS:PEBO) | 4.47% | ★★★★★★ |
Guaranty Trust Holding (NGSE:GTCO) | 6.90% | ★★★★★★ |
Globeride (TSE:7990) | 4.06% | ★★★★★★ |
GakkyushaLtd (TSE:9769) | 4.51% | ★★★★★★ |
China South Publishing & Media Group (SHSE:601098) | 4.35% | ★★★★★★ |
FALCO HOLDINGS (TSE:4671) | 6.67% | ★★★★★★ |
Kwong Lung Enterprise (TPEX:8916) | 6.32% | ★★★★★★ |
Citizens & Northern (NasdaqCM:CZNC) | 5.46% | ★★★★★★ |
Financial Institutions (NasdaqGS:FISI) | 4.32% | ★★★★★☆ |
Premier Financial (NasdaqGS:PFC) | 4.32% | ★★★★★☆ |
Click here to see the full list of 1936 stocks from our Top Dividend Stocks screener.
Let's review some notable picks from our screened stocks.
FinecoBank Banca Fineco
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: FinecoBank Banca Fineco S.p.A. offers a range of banking and investment products and services, with a market cap of approximately €9.07 billion.
Operations: FinecoBank Banca Fineco S.p.A. generates its revenue primarily from its banking segment, which amounts to €1.30 billion.
Dividend Yield: 4.5%
FinecoBank Banca Fineco reported a net income increase to €169.68 million for Q3 2024, up from €145.32 million the previous year, indicating solid earnings growth despite forecasts of a 1.2% annual decline over the next three years. The dividend yield is relatively low at 4.5%, and payments have been volatile over the past decade, though currently covered by earnings with a payout ratio of 67.9%.
Luyan PharmaLtd
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Luyan Pharma Co., Ltd. is involved in the research, development, production, and sale of human health products in China with a market cap of CN¥3.48 billion.
Operations: Luyan Pharma Co., Ltd.'s revenue segments include the research, development, production, and sale of human health products in China.
Dividend Yield: 3.3%
Luyan Pharma Ltd. reported stable earnings for the nine months ending September 2024, with net income slightly decreasing to CNY 257.35 million from CNY 261.98 million a year prior. The company offers a dividend yield of 3.34%, placing it in the top quartile of CN market dividend payers, supported by a low cash payout ratio of 23.3%. Despite its short dividend history under ten years, payments have been reliable and well-covered by earnings and cash flow.